FDA approves Pfizer’s leukemia drug

(Reuters) – The U.S. Food and Drug Administration (FDA) on Friday approved Pfizer Inc’s drug, Mylotarg, for certain patients with acute myeloid leukemia (AML), re-clearing a drug that had been pulled off the market in 2010.

The drug was cleared to treat adults with newly diagnosed AML and tumors expressing the CD33 antigen, as well as patients aged 2 years and older with CD33-positive AML who have relapsed, or did not respond to initial treatment.

The FDA said the drug has a boxed warning as it may cause severe or fatal liver damage, including blockage of veins in the liver. (reut.rs/2gv6KYu)

ESC: Triple Vascular Screening Reduces Deaths

BARCELONA – Non-invasive population-wide screening for high blood pressure, abdominal aortic aneurysm and peripheral artery disease appears to be life-saving, feasible and cost-effective, according to researchers who performed the Danish Viborg Vascular (VIVA) study that included 50,000 men.

When compared with the men who were not screened, there was a 7% reduction in mortality – or it required 169 screenings to save one life (P=0.01), said Jes Lindholt, MD, professor of vascular surgery,at Odense University Hospital, Denmark.

ESC: Frequent Smartphone Afib Monitoring Catches Arrhythmia

BARCELONA — Twice-weekly use of a smartphone device for single-lead electrocardiogram detection of atrial fibrillation caught more cases than usual care, although with a fairly low yield in seniors with afib risk factors.

Screening picked up 3.9-fold more atrial fibrillation than found in routine care — 19 versus five cases out of the evenly divided 1,001 participants (P=0.007), Julian Halcox, MD, of Swansea University in Wales, reported here at the European Society of Cardiology meeting and simultaneously online in Circulation.

Gout patient hospitalizations: what’s causing the increase?

August 31, 2017

An interview with Dr. Gurkirpal Singh, Stanford University, conducted by April Cashin-Garbutt, MA (Cantab)

Can you please outline the gout patient hospitalization data presented at the Annual European Congress of Rheumatology (EULAR) 2017?

We looked at all hospitalizations in patients with gout. The concern is that gout is often considered as a disease of just the joints, specifically of the big toe. Yet, there have been quite a lot of studies that have talked about the many other comorbidities that occur because of hyperuricemia and gout. The idea is that it’s not just the crystal deposits in the joint, but other consequences that are happening because of this disease in the rest of the body.